Characteristics and management of uterine sarcoma patients treated at the Tom Baker Cancer Centre

Abstract

The purpose of this study was to evaluate patients with uterine sarcoma from Southern Alberta to assess patterns of care and outcomes associated with treatment by a multidisciplinary team. Using the Alberta Cancer Registry database, charts of all uterine sarcoma patients treated between 1988 and 1997 in Southern Alberta were extracted. The majority of patients underwent definitive surgery. Adjuvant treatments were performed in selected patients at the discretion of the multidisciplinary tumor board. Demographics, management, and outcomes were collected into an electronic database. Eighty-seven patients were treated for uterine sarcoma at the Tom Baker Cancer Centre from 1988 to 1997. The 5-year overall survival rate was 48% and the 10-year overall survival rate was 21%. Univariate analysis demonstrated that stage, histologic subtype, and treatment with radiation therapy had a significant effect on local control and that stage and histologic subtype had a significant effect on survival. Stage was significant in the multivariate analysis for both local control (P = 0.008) and overall survival (P = 0.0001). Based on the findings in this series, stage remains a significant prognostic factor for patients with uterine sarcoma. Multidisciplinary care in the local setting reduced the use of adjuvant therapy without impacting adversely on survival or local control.

Uterine Sarcoma: Clinical Presentation, Treatment and Survival Outcomes in Thailand

“…Our data were consistent with Benito et al study which found CS in 48% and LMS in 22% (Benito et al, 2009). Contrast with other studies in Thailand, most common type are LMS .Other previous studies reported different findings, with similar frequency of CS and LMS (Kelly and Craighead, 2005;Koivisto et al, 2008;Park et al, 2008;Durnali et al, 2012). The small number of cases in each study might have exaggerated the different proportion of each uterine sarcoma type.…”

“…The small number of cases in each study might have exaggerated the different proportion of each uterine sarcoma type. Nevertheless, our study and all other previous studies found ESS or AS as the least common constituting only 10-30% (Kelly and Craighead, 2005;Koivisto et al, 2008;Park et al, 2008;Benito et al, 2009;Durnali et al, 2012). Our patients' mean age of 54 years was within the range of 50 to 62 years reported in other studies (Livi et al, 2003;Park et al, 2008).…”

“…Other studies reported 2-year or 3-year OS ranging from 48-64% (Kelly and Craighead, 2005;Koivisto et al, 2008;Park et al, 2008;Benito et al, 2009;Durnali et al, 2012). A possible reason for different outcomes was various prognostic factors found in each study.…”

“…Previous studies reported 59-82% of patients had abnormal uterine bleeding and 17-23% presented with mass (Kelly and Craighead, 2005;Park et al, 2008;Benito et al, 2009). These presenting symptoms and appropriate pre-operative investigation should lead to a correct preoperative diagnosis.…”

“…Their prognoses remained unchanged: overall 5-year survival ranged from 18% to 55% (Kelly and Craighead, 2005;Koivisto et al, 2008;Park et al, 2008;Durnali et al, 2012). Being rare tumors, large prospective studies or randomized controlled trials of uterine sarcoma are 1760 not common.…”